Search Clinical Trials
Completed
The Effect of Prolonged Pramlintide Infusion in Pediatric Diabetes (External Link)
The Diabetes Control and Complications Trial (DCCT) showed that improving blood sugar control for individuals with Type 1 diabetes (T1DM) stopped or delayed the onset of long-term complications. As a …
Baylor Role:
Lead Sponsor
Completed
EBV-Specific CTLs Following CD45 Antibody to Patients With Epstein-Barr Virus (EBV) + Nasopharyngeal Carcinoma (NPC) (External Link)
Three different doses of CTL will be evaluated: dose level I: 2 x 10e7/m2; dose level II: 5 x 10e7/m2; dose level III: 1 x 10e8/m2 Day 1 YTH 24/54 …
Baylor Role:
Lead Sponsor
Completed
Fludarabine, Cyclophosphamide, and Alemtuzumab in Treating Patients With Recurrent or Metastatic Renal Cell Carcinoma (Kidney Cancer) Undergoing Allogeneic Stem Cell Transplantation (External Link)
OBJECTIVES: - Determine the safety and feasibility of fludarabine, cyclophosphamide, and alemtuzumab in patients with recurrent or metastatic renal cell carcinoma undergoing HLA-matched allogeneic stem cell transplantation. OUTLINE: This is …
Baylor Role:
Lead Sponsor
Completed
Anti-Human CD45 Monoclonal Antibodies in Patients With Advanced Leukemia Prior to Allogeneic Stem Cell Transplantation (External Link)
Patients are given high doses of chemotherapy before receiving a stem cell transplant to keep their immune system from rejecting the donor stem cells and to kill any diseased cells …
Baylor Role:
Lead Sponsor
Completed
Treatment of B-CLL With Human IL-2 and CD40 Ligand and Plasmid Gene Modified Autologous Tumor Cells (External Link)
This is a phase I trial to assess the safety of a dose escalation of hCD40L-expressing autologous tumor cells with a fixed dose of recombinant hIL-2 gene transduced autologous leukemic …
Baylor Role:
Lead Sponsor
Completed
Treatment of Chronic Lymphocytic B-Leukemia With IL-2 and CD-40 Autologous Tumor Cells (External Link)
Before starting treatment some of the cancer cells will be taken from the patient and separated in the laboratory. A specially produced human virus (adenovirus) that carries the IL-2 gene …
Baylor Role:
Lead Sponsor
Completed
Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation of Patients With Hematological Diseases (External Link)
CAMPATH-1H will be given as a daily IV infusion for three days. Fludarabine will be given as a daily IV infusion for four days. Anti-CD45 will be given as a …
Baylor Role:
Lead Sponsor
Completed
The Role of Amylin and Glucagon in T1DM (External Link)
Objective: To develop a new treatment approach in the prevention of hypo and hyperglycemia in children with type 1diabetes. Background/Rationale: The diabetes control and complications trial (DCCT) showed that improving …
Baylor Role:
Lead Sponsor
Completed
Rituxan + BEAM and Auto Stem Cell Transplant for High Risk Lymphoma or Hodgkin's Disease (External Link)
Subjects will receive the chemotherapy through a plastic tube (catheter) placed into a vein under the collarbone. The antibody rituximab is given on the day of admission. The subject will …
Baylor Role:
Lead Sponsor
Completed
Treatment of Resistant Langerhans Cell Histiocytosis With ENBREL (External Link)
After subjects have completed the pretreatment evaluations, they will receive an injection of Enbrel - the study drug -(given under the skin) twice weekly. If the subjects disease stabilizes or …
Baylor Role:
Lead Sponsor